Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

被引：0
作者：
Buisson, A. [1 ]
Nachury, M. [2 ]
Fumery, M. [3 ]
Guilmoteau, T. [1 ]
Leclerc, E. [1 ]
Altwegg, R. [4 ]
Serrero, M. [5 ]
Mathieu, N. [6 ]
Treton, X. [7 ]
Vuitton, L. [8 ]
Pereira, B. [9 ]
Amiot, A. [10 ]
Bouguen, G. [11 ]
机构：
[1] Univ Hosp Estaing, Dept Gastroenterol, IBD Unit, Clermont Ferrand, France
[2] CHRU Lille, IBD Unit, Lille, France
[3] CHU Amiens, IBD Unit, Amiens, France
[4] CHU Montpellier, IBD Unit, Montpellier, France
[5] AP HM, IBD Unit, Marseille, France
[6] CHU Grenoble, IBD Unit, Grenoble, France
[7] AP HP Beaujon Hosp, IBD Unit, Paris, France
[8] CHU Besancon, IBD Unit, Besancon, France
[9] Univ Hosp Estaing, DRCI Biostat Unit, Clermont Ferrand, France
[10] AP HP Creteil Hosp, IBD Unit, Paris, France
[11] CHU Rennes, IBD Unit, Rennes, France
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP76
引用
收藏
页码：I120 / I120
页数：1
相关论文
共 50 条
  • [31] Comparative Effectiveness of Ustekinumab Versus Vedolizumab in Treating Crohn's Disease After Failure of Anti-TNF Agents: Real-World Evidence
    Alamer, A.
    Al Lehaibi, L.
    Alomar, M.
    Aldhuwayan, F.
    Alshouish, S.
    Al-Ali, A.
    Almudhry, Z.
    Almulhim, A.
    Althagafi, A.
    Aldosari, S.
    Alameel, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1297 - I1297
  • [32] Comparative Effectiveness and Safety of Upadacitinib and Vedolizumab in Anti-TNF Experienced Patients with Ulcerative Colitis: A Retrospective Study
    Sror, N.
    Leibovitzh, H.
    Hirsch, A.
    Thurm, T.
    Ron, Y.
    Maharshak, N.
    Cohen, N. A.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1573 - i1574
  • [33] MUCOSAL HEALING WITH A SECOND ANTI-TNF IN PATIENTS WITH ULCERATIVE COLITIS AFTER THE FAILURE OF THE PREVIOUS ANTI-TNF TREATMENT
    Papa, A.
    Pugliese, D.
    De Vitis, I.
    D'Aversa, F.
    Landi, R.
    Felice, C.
    Guidi, L.
    Armuzzi, A.
    Rapaccini, G. L.
    DIGESTIVE AND LIVER DISEASE, 2017, 49 : E203 - E203
  • [34] One-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib Versus Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States
    Dalal, R.
    Sharma, P.
    Bains, K.
    Pruce, J.
    Allegretti, J.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 677 - 678
  • [35] ONE-YEAR COMPARISON OF CLINICAL AND ENDOSCOPIC OUTCOMES OF TOFACITINIB VERSUS VEDOLIZUMAB FOR ULCERATIVE COLITIS AFTER ANTI-TUMOR NECROSIS FACTOR FAILURE: A REAL-WORLD COHORT STUDY IN THE UNITED STATES
    Dalal, Rahul S.
    Sharma, Puza P.
    Bains, Kanwal
    Pruce, Jordan C.
    Allegretti, Jessica R.
    GASTROENTEROLOGY, 2023, 164 (06) : S651 - S651
  • [36] Tofacitinib versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
    Gros, B.
    Constantine-Cooke, N.
    Kennedy, J.
    Elford, A. T.
    O'Hare, C.
    Noble, C.
    Jones, G. R.
    Arnott, I. D.
    Plevris, N.
    Lees, C. W.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I102 - I103
  • [37] TOFACITINIB VERSUS VEDOLIZUMAB AMONG BIO-NAIVE PATIENTS WITH ULCERATIVE COLITIS: A REAL-WORLD PROPENSITY-WEIGHTED COMPARISON
    Gros, Beatriz
    Constantine-Cooke, Nathan
    Kennedy, Jake
    Elford, Alexander T.
    O'Hare, Claire
    Noble, Colin
    Jones, Gareth-Rhys
    Arnott, Ian
    Plevris, Nikolas
    Lees, Charlie W.
    GASTROENTEROLOGY, 2024, 166 (05) : S1426 - S1426
  • [38] Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study
    Hupe, Marianne
    Riviere, Pauline
    Nancey, Stephane
    Roblin, Xavier
    Altwegg, Romain
    Filippi, Jerome
    Fumery, Mathurin
    Bouguen, Guillaume
    Peyrin-Biroulet, Laurent
    Bourreille, Arnaud
    Caillo, Ludovic
    Simon, Mireille
    Goutorbe, Felix
    Laharie, David
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (09) : 852 - 860
  • [39] Effectiveness of a second-line anti-TNFα agent compared to a different mechanism of action after first anti-TNFα failure in ulcerative colitis: CambiaCU Study
    Lopez-Vico, M.
    Hernandez-Martinez, A.
    Soto-Escribano, P.
    Rojas-Feria, M.
    Cornejo-Jimenez, A.
    Caballero-Mateos, A. M.
    Trapero-Martinez, A. M.
    Sanchez-Capilla, A. D.
    Cabello-Tapia, M. J.
    Martin-Rodriguez, M. D. M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1293 - I1293
  • [40] Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib
    Kappelman, Michael D.
    Long, Millie D.
    Zhang, Xian
    Lin, Feng-Chang
    Weisbein, Laura
    Chen, Wenli
    Burris, Jessica
    Dorand, Jennifer E.
    Parlett, Lauren E.
    Fehlmann, Tara
    Brensinger, Colleen M.
    Haynes, Kevin
    Nair, Vinit
    Kaul, Alan F.
    Dobes, Angela
    Lewis, James D.
    CROHNS & COLITIS 360, 2023, 5 (03)
12345